Author:
Yun Jihoon,Kim Jihyun,Chung Jihyun,Hwang Su-Jeong,Park Su Jin
Funder
Samsung Bioepis Co., Ltd.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference10 articles.
1. Herceptin (trastuzumab) summary of product characteristics. Roche Registration GmbH.
https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf
. Accessed 28 Feb 2019.
2. Ontruzant (trastuzumab) summary of product characteristics. Samsung Bioepis NL B.V.
https://www.ema.europa.eu/en/documents/product-information/ontruzant-epar-product-information_en.pdf
. Accessed 28 Feb 2019.
3. Pivot X, Curtit E, Lee YJ, et al. A randomized phase I pharmacokinetic study comparing biosimilar candidate SB3 and trastuzumab in healthy male subjects. Clin Ther. 2016;38(7):1665–73.
4. Pivot X, Bondarenko I, Nowecki Z, et al. Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early breast cancer. J Clin Oncol. 2018;36(10):968–74.
5. Pivot X, Bondarenko I, Nowecki Z, et al. A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: final safety, immunogenicity and survival results. Eur J Cancer. 2018;93:19–27.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献